( ro de Investigación Médic...)Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria,Health

CIMA is a biomedical research project which aims to improve clinical practice. It was started at the University of Navarra in order to give an organized and systematic response to the need to fight against severe diseases that currently cannot be cured.

About the Porphyrins and Porphyrias Congress 2007

The Porphyrins & Porphyrias meetings are biennial events organised with the aim of providing an environment for active participation of both experienced and new researchers in the field. This years event is held in Rotterdam, The Netherlands between April 29th and May 3rd.

There will be presentations and discussions on all haem synthesis enzymes, including structure and function, molecular/genetic aspects and clinical syndromes. Haem degradation (including haem oxygenase, bilirubinaemias etc.) and iron related topics, and general porphyria. Diagnostics/therapies/clinical issues, including drug porphyrinogenicity will also be covered.

For further information, please contact:

AMT:

Prof. Sander Van Deventer, CSO

Phone: +31 20 566 7394

Email: s.vandeventer@amtbv.com

Northbank Communications:

Adam Michael, Account Director

Phone: +44 20 7268 3233

Email: amt@northbankcommunications.com

Best regards

Holly Griffiths Account Executive --------------------------------------------- Direct line: +44 (0)20 7268 3241 Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102 www.northbankcommunications.com <http://www.northbankcommunications.com/>

Northbank Communications Ltd 85 Tottenham Court Road, London, W1T 4TQ, UK